Advanced

The European Vasculitis Society 2016 Meeting Report

Bajema, Ingeborg M.; Bruijn, Jan A.; Casian, Alina; Cid, Maria C.; Csernok, Elena; van Daalen, Emma; Harper, Lorraine; Hauser, Thomas; Little, Mark A. and Luqmani, Raashid A., et al. (2017) In Kidney International Reports 2(6). p.1018-1031
Abstract

The 2016 European Vasculitis Society (EUVAS) meeting, held in Leiden, the Netherlands, was centered around phenotypic subtyping in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV). There were parallel meetings of the EUVAS petals, which here report on disease assessment; database; and long-term follow-up, registries, genetics, histology, biomarker studies, and clinical trials. Studies currently conducted will improve our ability to discriminate between different forms of vasculitis. In a project that involves the 10-year follow-up of AAV patients, we are working on retrieving data on patient and renal survival, relapse rate, the cumulative incidence of malignancies, and comorbidities. Across Europe, several... (More)

The 2016 European Vasculitis Society (EUVAS) meeting, held in Leiden, the Netherlands, was centered around phenotypic subtyping in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV). There were parallel meetings of the EUVAS petals, which here report on disease assessment; database; and long-term follow-up, registries, genetics, histology, biomarker studies, and clinical trials. Studies currently conducted will improve our ability to discriminate between different forms of vasculitis. In a project that involves the 10-year follow-up of AAV patients, we are working on retrieving data on patient and renal survival, relapse rate, the cumulative incidence of malignancies, and comorbidities. Across Europe, several vasculitis registries were developed covering over 10,000 registered patients. In the near future, these registries will facilitate clinical research in AAV on a scale hitherto unknown. Current studies on the genetic background of AAV will explore the potential prognostic significance of genetic markers and further refine genetic associations with distinct disease subsets. The histopathological classification of ANCA-associated glomerulonephritis is currently evaluated in light of data coming out of a large international validation study. In our continuous search for biomarkers to predict clinical outcome, promising new markers are important subjects of current research. Over the last 2 decades, a host of clinical trials have provided evidence for refinement of therapeutic regimens. We give an overview of clinical trials currently under development, and consider refractory vasculitis in detail. The goal of EUVAS is to stimulate ongoing research in clinical, serological, and histological management and techniques for patients with systemic vasculitis, with an outlook on the applicability for clinical trials.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
keywords
ANCA, renal outcome, therapy, vasculitis
in
Kidney International Reports
volume
2
issue
6
pages
14 pages
publisher
Elsevier Inc.
external identifiers
  • scopus:85040727203
ISSN
2468-0249
DOI
10.1016/j.ekir.2017.09.008
language
English
LU publication?
yes
id
8bc8548a-633c-4edb-bd89-f40a961e81cd
date added to LUP
2018-02-05 16:20:42
date last changed
2019-03-12 04:04:18
@article{8bc8548a-633c-4edb-bd89-f40a961e81cd,
  abstract     = {<p>The 2016 European Vasculitis Society (EUVAS) meeting, held in Leiden, the Netherlands, was centered around phenotypic subtyping in antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV). There were parallel meetings of the EUVAS petals, which here report on disease assessment; database; and long-term follow-up, registries, genetics, histology, biomarker studies, and clinical trials. Studies currently conducted will improve our ability to discriminate between different forms of vasculitis. In a project that involves the 10-year follow-up of AAV patients, we are working on retrieving data on patient and renal survival, relapse rate, the cumulative incidence of malignancies, and comorbidities. Across Europe, several vasculitis registries were developed covering over 10,000 registered patients. In the near future, these registries will facilitate clinical research in AAV on a scale hitherto unknown. Current studies on the genetic background of AAV will explore the potential prognostic significance of genetic markers and further refine genetic associations with distinct disease subsets. The histopathological classification of ANCA-associated glomerulonephritis is currently evaluated in light of data coming out of a large international validation study. In our continuous search for biomarkers to predict clinical outcome, promising new markers are important subjects of current research. Over the last 2 decades, a host of clinical trials have provided evidence for refinement of therapeutic regimens. We give an overview of clinical trials currently under development, and consider refractory vasculitis in detail. The goal of EUVAS is to stimulate ongoing research in clinical, serological, and histological management and techniques for patients with systemic vasculitis, with an outlook on the applicability for clinical trials.</p>},
  author       = {Bajema, Ingeborg M. and Bruijn, Jan A. and Casian, Alina and Cid, Maria C. and Csernok, Elena and van Daalen, Emma and Harper, Lorraine and Hauser, Thomas and Little, Mark A. and Luqmani, Raashid A. and Mahr, Alfred and Ponte, Cristina and Salama, Alan and Segelmark, Mårten and Suzuki, Kazuo and Sznajd, Jan and Teng, Y. K.Onno and Vaglio, Augusto and Westman, Kerstin and Jayne, David},
  issn         = {2468-0249},
  keyword      = {ANCA,renal outcome,therapy,vasculitis},
  language     = {eng},
  number       = {6},
  pages        = {1018--1031},
  publisher    = {Elsevier Inc.},
  series       = {Kidney International Reports},
  title        = {The European Vasculitis Society 2016 Meeting Report},
  url          = {http://dx.doi.org/10.1016/j.ekir.2017.09.008},
  volume       = {2},
  year         = {2017},
}